Investing in ambitious life science businesses
Discovery Park Ventures is our very own investment fund, keen on supporting and mentoring exciting innovators with novel business ideas.
Launched in May 2022, Discovery Park Ventures is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth.
Investing on behalf of private individuals, the £3m fund supports exciting early-stage companies at start-up or to help them leverage non-dilutive funding and has plans to expand to up to £25m in the next three years.
The fund isn’t guaranteed to occupiers of Discovery Park, though our supportive team are always ready to open doors and make connections into other investment opportunities and networks where possible. Similarly, investee companies do not necessarily need to be based at Discovery Park but are likely to have a strong collaborative relationship.
£3m investment fund for early-stage innovators
Experienced team to mentor and guide
Access to wider network of experts
Focus on disruptive technologies
DPV portfolio
Vitarka Therapeutics is a pre-clinical stage Biotech focused on the development of RNAi therapies and non-viral delivery platform technology.
Vitarka Therapeutics
Vitarka Therapeutics is a pre-clinical stage Biotech focused on the development of RNAi therapies and non-viral delivery platform technology.
VisusNano is a pre-clinical company developing a pipeline of exciting drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery.
VisusNano
VisusNano is a pre-clinical company developing a pipeline of exciting drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery.
BoobyBiome is conducting groundbreaking breast milk research, fuelling products that deliver vital microbes to support infant gut flora and boost early immune system development.
Booby Biome
BoobyBiome is conducting groundbreaking breast milk research, fuelling products that deliver vital microbes to support infant gut flora and boost early immune system development.
Neobe Therapeutics are working to improve cancer immunotherapy through the use of engineered live biotherapeutics, enabling success in patients with immune excluded tumours.
Neobe Therapeutics
Neobe Therapeutics are working to improve cancer immunotherapy through the use of engineered live biotherapeutics, enabling success in patients with immune excluded tumours.
Ignota Labs have developed a proprietary suite of AI-driven toxicity prediction tools, enabling early-stage drug discovery scientists to identify and understand safety liabilities at scale.
Ignota Labs
Ignota Labs have developed a proprietary suite of AI-driven toxicity prediction tools, enabling early-stage drug discovery scientists to identify and understand safety liabilities at scale.
Oxford Medical Products has developed ‘Sirona’, a gastroretentive hydrogel platform technology that is currently in human clinical trials as a weight-loss treatment and has potential applications to drug and nutraceutical delivery, and biosensors.
Oxford Medical Products
Oxford Medical Products has developed ‘Sirona’, a gastroretentive hydrogel platform technology that is currently in human clinical trials as a weight-loss treatment and has potential applications to drug and nutraceutical delivery, and biosensors.
Optceutics Ltd. uses the PK-Eye model, a dynamic ophthalmic pharmacokinetic model, to speed and enhance the development of ocular formulations.
Optceutics
Optceutics Ltd. uses the PK-Eye model, a dynamic ophthalmic pharmacokinetic model, to speed and enhance the development of ocular formulations.
Discovery Park Ventures is a very welcome addition to our investor base. With Sirona in clinical trials this is an exciting stage of development for Oxford Medical Products and we look forward to working with the DPV team as we progress towards the market.
Dr Camilla Easter , CEO of Oxford Medical Products
We are delighted to be backed by Discovery Park Ventures. Its team’s extensive experience of company building, business development and fundraising will be invaluable to Ignota Labs as we create partnerships around our toxicity screening technology and build our offering.
Sam Windsor , CEO of Ignota Labs
We’re delighted to welcome Discovery Park Ventures as a new investor as we enter this exciting clinical phase of development. As a Discovery Park tenant we have found the environment very supportive and this investment is another way in which the Park is driving our growth.
Dr Joanna Gould , CEO, VisusNano
We’d like to thank Discovery Park Ventures for its belief in our innovative approach to cancer treatment and therapeutic delivery, and welcome it as a shareholder. Vitarka Therapeutics looks forward to working with DPV as we generate our proof of concept data3.
Dr Vineeta Tripathi , CEO, Vitarka Therapeutics
